Skip to content
Research library

Clinical research overview

This library brings together peer-reviewed studies on Mesenchymal Stem Cells (MSCs) across a wide range of medical indications. Each study contributes to a deeper understanding of how MSCs support repair, regeneration, and immune balance in the body.
Crohn's disease Aging frailty Osteoarthritis
Acute respiratory disease syndrome Graft versus host disease (GvHD) Multiple sclerosis Liver cirrhosis Diabetes type II Diabetes type I Chronic low back pain Chronic obstructive pulmonary disease (COPD) Alzheimer's disease Rheumatoid arthritis

Multiple sclerosis

Research into Mesenchymal Stem Cells (MSCs) in Multiple Sclerosis (MS) is growing, with studies focusing on safety, feasibility, and potential neurological effects. Investigations explore whether MSCs may support repair processes in the central nervous system and modulate immune responses. Multiple Sclerosis is a chronic autoimmune disease in which the immune system attacks the protective myelin sheath around nerves. This leads to a wide range of symptoms, including fatigue, vision problems, muscle weakness, and difficulties with coordination. Current treatments may slow progression but do not reverse existing damage. MSC studies in MS remain exploratory, but early findings suggest possible roles in neuroprotection, inflammation control, and repair support. Continued research is essential for clarifying the potential of MSC-based approaches within the broader field of neurodegenerative disease treatment.

Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis

Neil H Riordan, et al.
Multiple sclerosis (MS) is a progressively debilitating neurological condition in which the immune system abnormally erodes the myelin sheath insulating the nerves. Mesenchymal stem cells (MSC) have been used in the last decade to safely treat certain immune and inflammatory conditions.
More
Read study

Adipose-derived mesenchymal stem cells (AdMSC) for the treatment of secondary-progressive multiple sclerosis: A triple blinded, placebo controlled, randomized phase I/II safety and feasibility study

Oscar Fernández, et al.
Currently available treatments for secondary progressive multiple sclerosis(SPMS) have limited efficacy and/or safety concerns. Adipose-mesenchymal derived stem cells(AdMSCs) represent a promising option and can be readily obtained using minimally invasive procedures.
More
Read study

Neurophysiological outcomes following mesenchymal stem cell therapy in multiple sclerosis

François Tremblay, et al.
To report on neurophysiological outcomes derived from transcranial magnetic stimulation (TMS) following autologous mesenchymal stem cells (aMSCs) therapy in patients with multiple sclerosis (MS).
More
Read study

Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive Multiple Sclerosis

Panayiota Petrou, et al.
After 6 months of MSC-IT treatment, CSF levels of NF-L significantly decreased compared to baseline (P = .026). 9 out of 15 patients had a reduction in NF-L levels of over 50% compared to 5 out of 15 in the MSC-IV group and 1 out of 15 in the placebo group (P = .001 for MSC-IT vs. placebo). CXCL13 levels were also reduced but not significantly.
More
Read study

Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis

Dimitrios Karussis, et al.
21 patients had mild injection-related adverse effects, such as fever, and 15 experienced headaches. No major adverse effects were reported during follow-up. MRI showed the possible migration of MSCs in the meninges, subarachnoid space, and spinal cord. The ALSFRS score remained stable, while the EDSS score improved. Immunological analysis indicated an increase in regulatory T cells and a decrease in lymphocyte response. Myeloid dendritic cells also showed changes after MSC transplantation.
More
Read study